Table of Contents
Overview
The global oligonucleotide synthesis market is projected to grow from USD 9.1 billion in 2023 to USD 44.9 billion by 2033, registering a CAGR of 17.3%. Growth is strongly linked to rising adoption in genetic research and molecular diagnostics. Expanding applications in genomics, transcriptomics, and proteomics are driving higher demand for custom oligonucleotides. Pharmaceutical companies and research institutions are increasingly utilizing these molecules for gene editing, sequencing, synthetic biology, and PCR assays. This growing use case base is creating strong momentum for the overall expansion of the market.
Advancements in genomics and synthetic biology are another major growth factor. The development of next-generation sequencing (NGS), CRISPR, and advanced genome-editing tools has heightened the demand for high-quality oligonucleotides. Personalized medicine and precision therapeutics rely heavily on primers, probes, and antisense molecules derived from oligonucleotides. These innovations are enabling targeted diagnostics and therapies, reinforcing their role as an essential component of modern biomedical research and clinical applications.
The increasing prevalence of chronic and genetic disorders is significantly influencing market growth. The global burden of cancer, cardiovascular conditions, and rare genetic diseases is expanding the use of oligonucleotide-based therapies. Antisense oligonucleotides, aptamers, and small interfering RNAs (siRNAs) are now widely applied in drug discovery and advanced therapeutics. As healthcare systems emphasize nucleic acid-based treatments, the demand for such molecules is anticipated to remain strong throughout the forecast period.
Investments in biopharmaceutical research and development are also boosting the sector. Leading pharmaceutical and biotechnology firms are allocating resources toward nucleic acid-based therapeutics and diagnostic platforms. In parallel, government funding initiatives for genomics and gene therapy research are increasing support. Collaborations between private companies and research institutions are expanding synthesis capabilities and improving production efficiency. This combination of private investment and public support is enhancing the market outlook.
Technological innovations and outsourcing trends are further shaping the industry. Automated DNA/RNA synthesizers, enzymatic synthesis methods, and high-throughput platforms are improving cost-effectiveness and scalability. These technologies allow production of longer and more complex molecules with reduced error rates. At the same time, pharmaceutical companies are outsourcing production to contract manufacturing organizations (CMOs) to lower costs and ensure GMP-grade supply. Growing regulatory approvals for oligonucleotide-based drugs have further validated the technology, encouraging expansion of the therapeutic pipeline and strengthening industry confidence.
Key Takeaways
- In 2023, the global oligonucleotide synthesis market was valued at USD 9.1 billion and is projected to expand at a 17.3% CAGR.
- Oligonucleotide-based drugs represented 38.1% of the total market in 2023, primarily fueled by rising demand for advanced targeted therapeutic approaches.
- Pharmaceutical and biotechnology companies dominated revenue streams in 2023, accounting for 34.6% of global market earnings through consistent investments in oligonucleotide development.
- Therapies addressing cancer and neurological disorders are expected to strengthen oligonucleotide revenues, driving the therapeutic segment toward a 42.2% market share.
- North America remained the leading market in 2023, capturing 40.2% revenue share, largely due to established healthcare infrastructure and high R&D expenditure.
- Asia-Pacific emerged as the fastest-growing region, with Japan and China making substantial investments in oligonucleotide research and development initiatives.
- Key market participants include Thermo Fisher Scientific, Merck & Co., and GE Healthcare, recognized for their strong product portfolios and strategic industry presence.
Regional Analysis
North America dominated the oligonucleotide synthesis market in 2023, holding a 40.2% revenue share. This leadership was supported by the approval of oligonucleotide-based drugs by the FDA and the region’s strong focus on R&D. Advanced healthcare infrastructure further strengthened its position, along with the growing use of oligonucleotides by pharmaceutical companies. Strategic collaborations and partnerships also contributed to this growth. Moreover, governmental initiatives and the presence of a robust healthcare system created a favorable environment for the adoption of innovative therapies.
The region’s advantage is expected to persist due to continued investments in research activities. Pharmaceutical and biotechnology companies in North America are heavily engaged in using oligonucleotides for drug discovery and development. Increasing collaborations between industry and academia are further boosting innovation. Favorable regulatory frameworks also support faster product approvals. The combination of advanced facilities, skilled professionals, and significant funding ensures that the region maintains its lead in oligonucleotide synthesis. This ongoing momentum underpins future growth prospects.
Asia Pacific, on the other hand, is expected to be the fastest-growing region in this market. The growth is driven by advancements in genomic studies and rising adoption of sequencing and PCR technologies. China and Japan, in particular, are making large-scale investments in genomics research. This is improving their potential to capture market share. The region is also witnessing a rise in product approvals and new product launches, which accelerate market expansion. Strong focus on research, coupled with healthcare advancements, ensures sustained regional growth.
Segmentation Analysis
In 2023, the oligonucleotide-based drugs segment dominated the global oligonucleotide synthesis market with a 38.1% share. The strong performance of this segment is mainly due to the rising demand for targeted therapies. Advancements in technologies, such as CRISPR/Cas9 gene editing and RNA interference (RNAi), have widened the applications of oligonucleotide-based drugs. These innovations have strengthened the growth outlook. Regulatory support from agencies like the FDA, offering streamlined approval processes, is also contributing to the rapid expansion of this market segment.
Pharmaceutical and biotechnology companies accounted for the largest revenue share of 34.6% in 2023. This was driven by their heavy investment in R&D activities. The growing number of FDA and EMA-approved oligonucleotide therapies, now totaling 14, supports this trend. Companies are also prioritizing the treatment of rare diseases, with about 200 clinical studies and over 600 preclinical trials currently underway. These developments highlight the increasing involvement of pharmaceutical and biotechnology companies in advancing oligo-based therapies and expanding their role in healthcare innovation.
The global oligonucleotide synthesis market is categorized into four segments: oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. Among these, oligonucleotide-based drugs remain the largest and fastest-growing category. Their high specificity and efficacy make them a preferred choice for various medical conditions. The focus on precision medicine and personalized treatments further enhances their adoption. Continuous research and development activities are expected to bring forward new therapeutic solutions. As a result, the oligonucleotide-based drugs segment is forecasted to witness strong growth and innovation in the coming years.
Key Players Analysis
The oligonucleotide synthesis market is fragmented, with numerous players competing through various strategies. Acquisitions in emerging markets, distribution partnerships, and collaborations in new technology development are commonly adopted tactics. These approaches strengthen market positions and contribute to dynamic competition among established firms. Companies are using such strategies to expand their global presence and improve their technological capabilities. This creates an environment where market growth is influenced by continuous consolidation, partnerships, and joint efforts toward advancing synthesis technologies.
In addition, industry participants are focused on expanding and diversifying their product portfolios. The introduction of new oligonucleotide synthesis solutions helps to meet the growing demand from pharmaceutical and biotechnology sectors. This product innovation not only strengthens competitiveness but also improves operational scale. As leading players continue to emphasize technological development and portfolio expansion, competition in the market intensifies. Consequently, these initiatives are shaping the industry landscape, enhancing growth prospects, and reinforcing the dominance of prominent companies.
Market Key Players
- Thermo Fisher Scientific, Inc.
- Merck – Co., Inc.
- GE Healthcare Dharmacon Inc.
- Agilent Technologies
- Bio-synthesis
- Kaneka Eurogentec S.A.
- Integrated DNA Technologies, Inc.
- BioAutomation
- LGC Biosearch Technologies
- Other Key Players
Conclusion
The global oligonucleotide synthesis market is positioned for strong growth, supported by expanding applications in genomics, molecular diagnostics, and precision medicine. Increasing use in drug discovery, gene editing, and personalized therapies highlights its vital role in modern healthcare. Demand is being further driven by advancements in next-generation sequencing and CRISPR technologies, alongside the growing burden of chronic and genetic disorders. Strategic collaborations, rising R&D investments, and supportive regulatory frameworks are reinforcing industry expansion. With North America leading and Asia-Pacific emerging rapidly, the market is expected to continue its upward trajectory, shaped by innovation, outsourcing trends, and expanding adoption across pharmaceutical and biotechnology sectors.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
